Beam Therapeutics Inc (BEAM) concluded trading on Wednesday at a closing price of $21.46, with 3.95 million shares of worth about $84.72 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -15.45% during that period and on July 09, 2025 the price saw a gain of about 5.71%. Currently the company’s common shares owned by public are about 100.56M shares, out of which, 89.78M shares are available for trading.
Stock saw a price change of 22.42% in past 5 days and over the past one month there was a price change of 15.53%. Year-to-date (YTD), BEAM shares are showing a performance of -7.02% which decreased to -13.47% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $13.52 but also hit the highest price of $35.25 during that period. The average intraday trading volume for Beam Therapeutics Inc shares is 2.07 million. The stock is currently trading 20.08% above its 20-day simple moving average (SMA20), while that difference is up 20.69% for SMA50 and it goes to -6.77% lower than SMA200.
Beam Therapeutics Inc (NASDAQ: BEAM) currently have 100.56M outstanding shares and institutions hold larger chunk of about 88.21% of that.
The stock has a current market capitalization of $2.16B and its 3Y-monthly beta is at 2.20. It has posted earnings per share of -$4.61 in the same period. It has Quick Ratio of 8.81 while making debt-to-equity ratio of 0.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BEAM, volatility over the week remained 7.76% while standing at 6.38% over the month.
Analysts are in expectations that Beam Therapeutics Inc (BEAM) stock would likely to be making an EPS of -1.09 in the current quarter, while forecast for next quarter EPS is -1.09 and it is -4.48 for next year. For the current quarter EPS, analysts have given the company a lowest target -1.4 which is -0.78 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -1.11 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -0.41% while it is estimated to decrease by -0.84% in next year. EPS is likely to grow at an annualized rate of -0.84% for next 5-years, compared to annual growth of -20.88% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on March 28, 2025 offering a Buy rating for the stock and assigned a target price of $42 to it. Coverage by Scotiabank stated Beam Therapeutics Inc (BEAM) stock as a Sector outperform in their note to investors on March 10, 2025, suggesting a price target of $40 for the stock. On January 29, 2025, Cantor Fitzgerald Upgrade their recommendations, while on November 06, 2024, Leerink Partners Upgrade their ratings for the stock with a price target of $39. Stock get a Sector outperform rating from Scotiabank on October 16, 2024.
